<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ctDNA | Christian Brueffer</title><link>https://www.brueffer.io/tag/ctdna/</link><atom:link href="https://www.brueffer.io/tag/ctdna/index.xml" rel="self" type="application/rss+xml"/><description>ctDNA</description><generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Wed, 27 Sep 2023 00:00:00 +0000</lastBuildDate><image><url>https://www.brueffer.io/media/icon_hu7422bdd1ad1d5b8840d6088d6ba7ed4c_15338_512x512_fill_lanczos_center_3.png</url><title>ctDNA</title><link>https://www.brueffer.io/tag/ctdna/</link></image><item><title>#898 Tumor-informed ctDNA detection as a marker for postoperative residual disease in epithelial ovarian cancer – results of a feasibility study</title><link>https://www.brueffer.io/publication/2023_esgo/</link><pubDate>Wed, 27 Sep 2023 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2023_esgo/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi="10.1136/ijgc-2023-ESGO.60"
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi="10.1136/ijgc-2023-ESGO.60"
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item><item><title>Abstract 5710: Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens</title><link>https://www.brueffer.io/publication/2023_aacr/</link><pubDate>Sat, 01 Apr 2023 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2023_aacr/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi="10.1158/1538-7445.AM2023-5710"
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi="10.1158/1538-7445.AM2023-5710"
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item><item><title>2022-RA-627-ESGO: Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer</title><link>https://www.brueffer.io/publication/2022_esgo/</link><pubDate>Thu, 20 Oct 2022 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2022_esgo/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi="10.1136/ijgc-2022-ESGO.868"
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi="10.1136/ijgc-2022-ESGO.868"
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item><item><title>Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer</title><link>https://www.brueffer.io/publication/2022_ovarian_cancer_ctdna/</link><pubDate>Fri, 15 Jul 2022 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2022_ovarian_cancer_ctdna/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi="https://doi.org/10.21203/rs.3.rs-1770497/v1"
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi="https://doi.org/10.21203/rs.3.rs-1770497/v1"
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item><item><title>Plasma circulating tumor DNA as a genomic biomarker for ovarian cancer</title><link>https://www.brueffer.io/publication/2019_ehgc/</link><pubDate>Tue, 01 Oct 2019 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2019_ehgc/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi=""
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi=""
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item><item><title>Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment</title><link>https://www.brueffer.io/publication/2019_fornvik_ctdna_vs_ctc_after_breast_compression/</link><pubDate>Mon, 01 Jul 2019 00:00:00 +0000</pubDate><guid>https://www.brueffer.io/publication/2019_fornvik_ctdna_vs_ctc_after_breast_compression/</guid><description>&lt;html>
&lt;style>
section {
background: white;
color: black;
border-radius: 1em;
padding: 1em;
left: 50% }
#inner {
display: inline-block;
display: flex;
align-items: center;
justify-content: center }
&lt;/style>
&lt;section>
&lt;div id="inner">
&lt;script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'>&lt;/script>
&lt;span style="float:left";
class="__dimensions_badge_embed__"
data-doi="10.1007/s10549-019-05326-5"
data-hide-zero-citations="true"
data-legend="always">
&lt;/span>
&lt;script async src="https://badge.dimensions.ai/badge.js" charset="utf-8">&lt;/script>
&lt;div style="float:right";
data-link-target="_blank"
data-badge-details="right"
data-badge-type="medium-donut"
data-doi="10.1007/s10549-019-05326-5"
data-condensed="true"
data-hide-no-mentions="true"
class="altmetric-embed">
&lt;/div>
&lt;/div>
&lt;/section></description></item></channel></rss>